Global Value Dossier has become a standard tool throughout the life sciences industry for supporting product launch and local Health Technology Assessment (HTA) submissions. There is a clear need for internal dissemination of both the value strategy for the product and the supporting evidence required for reimbursement. We understand an optimal GVD is concise and value-focused, with clear identification of the unmet need for a given patient population (value drivers) and specific messaging focused on how the product fulfills this unmet need (value messages). The key value messages should form the backbone for the GVD that, supported by the relevant, KEY evidence, creates a clear value story. We are an ideal partner for the regional and global pharma companies who have biosimilar and new molecules for EU, US and other HTAs globally.